# DESCRIPTION

## FIELD OF THE INVENTION

- relate to CD6-ALCAM pathway inhibitors

## BACKGROUND OF THE INVENTION

- define inflammatory and autoimmune diseases
- describe immune response
- discuss causes of diseases
- discuss treatment options
- highlight role of T cells
- describe lupus
- discuss pathogenesis of SLE
- describe B cell and T cell activity
- discuss antibody responses
- describe lupus nephritis
- discuss current treatment options
- highlight limitations of current treatments
- discuss need for more effective treatments

## SUMMARY OF THE INVENTION

- relate to treating inflammatory or autoimmune diseases
- identify subjects with CD6-ALCAM pathway inhibitor-sensitive disease
- determine soluble CD6 and/or ALCAM protein levels
- administer CD6-ALCAM pathway inhibitor if levels are elevated
- treat lupus nephritis with CD6-ALCAM pathway inhibitor
- identify subjects with lupus nephritis sensitive to CD6-ALCAM pathway inhibition
- determine soluble CD6 and/or ALCAM protein levels in lupus nephritis subjects
- administer CD6-ALCAM pathway inhibitor if levels are elevated in lupus nephritis subjects
- treat inflammatory or autoimmune diseases with CD6-ALCAM pathway inhibitor
- identify subjects with inflammatory or autoimmune diseases sensitive to CD6-ALCAM pathway inhibition
- determine soluble CD6 and/or ALCAM protein levels in inflammatory or autoimmune disease subjects
- administer CD6-ALCAM pathway inhibitor if levels are elevated in inflammatory or autoimmune disease subjects
- use CD6-ALCAM pathway inhibitor to treat lupus nephritis
- use CD6-ALCAM pathway inhibitor to treat inflammatory or autoimmune diseases
- determine CD6 and/or ALCAM mRNA levels
- administer CD6-ALCAM pathway inhibitor if mRNA levels are elevated
- treat lupus nephritis with CD6-ALCAM pathway inhibitor based on mRNA levels
- treat inflammatory or autoimmune diseases with CD6-ALCAM pathway inhibitor based on mRNA levels
- use CD6-ALCAM pathway inhibitor to treat lupus nephritis based on mRNA levels
- use CD6-ALCAM pathway inhibitor to treat inflammatory or autoimmune diseases based on mRNA levels
- identify subjects with lupus nephritis sensitive to CD6-ALCAM pathway inhibition based on mRNA levels
- identify subjects with inflammatory or autoimmune diseases sensitive to CD6-ALCAM pathway inhibition based on mRNA levels
- determine soluble CD6 and/or ALCAM protein levels in biological samples
- determine CD6 and/or ALCAM mRNA levels in biological samples
- use EQ001 as CD6-ALCAM pathway inhibitor
- use anti-CD6 antibody as CD6-ALCAM pathway inhibitor
- use humanized anti-CD6 antibody as CD6-ALCAM pathway inhibitor
- use anti-CD6 antibody that binds to domain 1 or 3 on CD6
- use anti-CD6 antibody that binds to domain 3 on CD6
- use anti-CD6 antibody selected from EQ001, ALZUMAb, UMCD6 mAb, Itolizumab, T1
- use anti-CD6 antibody produced by secreting hybridoma IOR-T1A
- use antigen binding fragment of anti-CD6 antibody
- use Fv, Fab, CDR1, CDR2, CDR3, combination of CDRs, variable region, heavy chain(s
- use anti-CD6 antibody with specific CDR sequences
- use anti-CD6 antibody with specific VH and VK sequences
- use anti-CD6 antibody with specific VH and VK sequences encoded by specific nucleotide sequences
- use anti-CD6 antibody with VH sequence at least 80% identical to specific sequence
- use anti-CD6 antibody with VK sequence at least 80% identical to specific sequence
- analyze blood, serum, urine, sputum, CSF, BALF, or stool samples
- detect elevated levels of soluble CD6 and/or ALCAM protein
- detect elevated levels of CD6 and/or ALCAM mRNA
- use single-plex ELISA, multiplex ELISA, bead-based immunocapture with FACs-based detection
- use bead-based immunocapture with ELISA-based detection, bead-based immunocapture with chemiluminescent-based detection
- use meso-scale diagnostic (MSD), quantitative western blot, high performance liquid chromatography (HPLC)
- use combination of detection methods

## BRIEF DESCRIPTION OF THE SEQUENCES

- describe SEQ ID NOs: 1-10

## DETAILED DESCRIPTION OF THE INVENTION

### General Methods

- introduce molecular biology and recombinant DNA techniques
- cite literature for further explanation
- describe conventional methods within the skill of the art

### Definitions

- define technical and scientific terms
- introduce articles "a" and "an"
- define "and/or"
- define "e.g."
- define "about"
- define "administering"
- define "binding partner"
- define "carrier"
- define "chimeric antibody"
- define "effective amount"
- define "therapeutically effective amount"
- define "prophylactically effective amount"
- define "humanized antibody"
- define "antibody fragment"
- define "VH"
- define "VK"
- define "antigen binding fragment"
- define "comprise" and "comprising"
- define "consisting of"
- define "consisting essentially of"
- define "modulating"
- define "polypeptide" and "protein"
- define "subject" or "patient"
- define "substantially" or "essentially"
- define "treatment" or "treating"
- describe incorporation of publications and references

### Overview

- introduce inflammatory/autoimmune diseases
- motivate soluble CD6/ALCAM as biomarkers
- describe CD6 protein structure
- summarize CD6 function in T-cell development
- describe CD6 function in T-cell activation
- introduce soluble CD6 (sCD6)
- describe sCD6 formation and function
- introduce ALCAM protein structure
- describe ALCAM function in T-cell regulation
- introduce ALCAM shedding
- describe ALCAM as a biomarker
- summarize CD6/ALCAM interactions in T-cell regulation
- introduce CD6 and ALCAM proteins
- describe prior art on CD6 and ALCAM antibodies
- motivate need for biomarkers for CD6-ALCAM pathway inhibition
- introduce itolizumab and its production methods
- describe uses of itolizumab in treating inflammatory diseases
- introduce method for identifying subjects with inflammatory disease sensitive to CD6-ALCAM pathway inhibition
- describe determining soluble CD6 and ALCAM protein levels
- introduce method for treating inflammatory disease with CD6-ALCAM pathway inhibitor
- describe administering CD6-ALCAM pathway inhibitor based on soluble protein levels
- introduce method for using CD6-ALCAM pathway inhibitor to treat lupus nephritis
- describe determining soluble CD6 and ALCAM protein levels in lupus nephritis
- introduce method for treating subject with CD6-ALCAM pathway inhibitor
- describe determining CD6-ALCAM pathway inhibitor-sensitive disease
- introduce method for predicting prognosis of subject with inflammatory disease
- describe determining change in soluble CD6 and ALCAM protein levels over time
- introduce method for predicting prognosis of subject with lupus nephritis
- describe determining change in soluble CD6 and ALCAM protein levels over time in lupus nephritis
- introduce method for determining whether subject has active inflammatory disease
- describe determining soluble CD6 and ALCAM protein levels in active disease
- introduce method for determining whether subject has active lupus nephritis
- describe determining soluble CD6 and ALCAM protein levels in active lupus nephritis
- introduce method for determining whether subject has transitioned from inactive to active inflammatory disease
- describe determining change in soluble CD6 and ALCAM protein levels over time in inactive disease
- introduce method for determining whether subject has transitioned from inactive to active lupus nephritis
- describe determining change in soluble CD6 and ALCAM protein levels over time in inactive lupus nephritis
- describe administering CD6-ALCAM pathway inhibitor in active disease
- describe administering CD6-ALCAM pathway inhibitor in active lupus nephritis
- describe administering CD6-ALCAM pathway inhibitor in transitioning disease
- describe administering CD6-ALCAM pathway inhibitor in transitioning lupus nephritis
- introduce itolizumab as CD6-ALCAM pathway inhibitor
- introduce EQ001 as CD6-ALCAM pathway inhibitor
- describe anti-CD6 antibodies as CD6-ALCAM pathway inhibitors
- describe anti-ALCAM antibodies as CD6-ALCAM pathway inhibitors
- describe antigen binding fragments as CD6-ALCAM pathway inhibitors
- describe CD6-ALCAM pathway inhibitors in general
- describe uses of CD6-ALCAM pathway inhibitors
- describe advantages of CD6-ALCAM pathway inhibitors
- describe limitations of prior art
- describe need for new methods for treating inflammatory diseases
- describe need for new biomarkers for CD6-ALCAM pathway inhibition
- describe importance of early detection of inflammatory disease
- describe importance of targeted treatment of inflammatory disease
- conclude with summary of disclosure

### Inflammatory or Autoimmune Diseases

- describe inflammatory or autoimmune diseases

### Samples

- describe sample sources
- specify sample types
- describe sample collection methods
- specify sample collection time courses
- describe sample uses
- specify sample sources for inflammatory kidney diseases
- specify sample sources for neuroinflammatory diseases
- specify sample sources for inflammatory bowel diseases
- specify sample sources for inflammatory lung diseases
- specify sample sources for systemic inflammatory diseases

### Detection Methods

- describe soluble CD6 protein detection
- describe soluble ALCAM protein detection
- specify detection methods
- describe single-plex ELISA
- describe multiplex ELISA
- describe bead-based immunocapture with FACs-based detection
- describe bead-based immunocapture with ELISA-based detection
- describe bead-based immunocapture with chemiluminescent-based detection
- describe meso-scale diagnostic (MSD)
- describe western blot
- describe quantitative western blot
- describe high performance liquid chromatography (HPLC)
- describe mass spectrometry
- describe qualitative detection
- describe quantitative detection
- describe standard curve creation
- describe CD6 and/or ALCAM polynucleotide detection
- describe mRNA expression detection
- describe nucleic acid hybridization methods
- describe quantitative sequencing technology

### Thresholds

- describe threshold determination methods
- specify diagnostic threshold for active LN
- describe Receiver Operating Characteristic (“ROC”) analysis
- describe predictive power calculation
- describe multiple decision threshold methods

### CD6-ALCAM Pathway Inhibitors

- introduce CD6-ALCAM pathway inhibitors
- define anti-CD6 antibody
- describe EQ001
- motivate anti-CD6 antibody as CD6-ALCAM pathway inhibitor
- summarize CD6-mediated downstream signaling in T cells
- describe role of CD6 in T cell development
- describe role of CD6 in T cell activation
- summarize phosphorylation of CD6
- describe anti-CD6 antibody as modulator of T cell function
- describe anti-CD6 antibody as inhibitor of T cell migration
- describe delivery of anti-CD6 antibody to subject
- introduce pharmaceutical compositions
- describe preparation of pharmaceutical compositions
- list components of pharmaceutical compositions
- describe EQ001 as pharmaceutical composition
- introduce combination therapies
- describe second active agent in combination therapy
- describe immunosuppressant as second active agent
- describe anti-ALCAM antibody as CD6-ALCAM pathway inhibitor
- describe small molecule inhibitor of CD6-ALCAM pathway
- introduce administration of CD6-ALCAM pathway inhibitor
- describe administration of CD6-ALCAM pathway inhibitor as monotherapy
- describe administration of CD6-ALCAM pathway inhibitor as combination therapy
- describe administration of EQ001 as combination therapy
- describe administration of EQ001 with steroid or immunosuppressant
- describe administration of EQ001 with corticosteroid
- describe administration of EQ001 with prednisone
- describe administration of EQ001 with mycophenolate and cyclophosphamide
- describe administration of EQ001 with anti-ALCAM antibody
- describe timing of administration of CD6-ALCAM pathway inhibitor
- describe modes of administration
- describe formulation of CD6-ALCAM pathway inhibitors
- list components of formulations
- describe preparation of formulations
- describe sustained-release preparations
- describe semipermeable matrices
- describe hydrogels
- describe copolymers
- describe non-degradable ethylene-vinyl acetate
- describe degradable lactic acid-glycolic acid copolymers
- describe administration routes
- describe intravenous administration
- describe subcutaneous administration
- describe dosage regimen
- describe therapeutically effective amount
- describe kit for performing methods

## EXAMPLES

- introduce ELISA-based detection of soluble CD6 and soluble ALCAM protein in urine of subjects with lupus nephritis

### ELISA-Based Detection of Soluble CD6 and Soluble ALCAM Protein in Urine of Subjects with Lupus Nephritis

- describe sample collection and treatment
- introduce ELISA kits for detecting soluble ALCAM and soluble CD6
- describe sample collection from cohorts
- compare concentrations of soluble CD6 and soluble ALCAM between cohorts
- observe increases in soluble CD6 and soluble ALCAM in certain subjects
- correlate increases with transition from inactive to active disease
- observe decreases in soluble CD6 and soluble ALCAM in certain subjects
- correlate decreases with transition from active to inactive disease
- support use of soluble CD6 and soluble ALCAM as biomarker of active lupus nephritis
- expand study to investigate use of urinary levels of soluble CD6 and soluble ALCAM as biomarker of disease progression in other inflammatory kidney diseases

### CD6 and ALCAM Expression are Significantly Elevated in Human Renal Tissue Biopsies and are Detectable in Urine Cells from Lupus Nephritis (LN) Patients

- introduce background and purpose of research
- describe analysis of publicly available RNASeq dataset
- mine public datasets using bioinformatics
- compare CD6 and ALCAM expression in control samples vs. LN patient samples
- analyze CD6 and ALCAM expression in T cells and macrophages
- analyze CD6 and ALCAM expression in renal epithelial cells
- correlate CD6 expression with LN stage
- analyze ALCAM expression in tubular cells and macrophages
- analyze urinary ALCAM protein levels in active LN patients
- conclude that LN patients have increased CD6+ T cells and ALCAM+ cells in kidneys and urine

### High Levels of Soluble CD6 and Soluble ALCAM Protein in Urine as a Biomarker for Sensitivity to Treatment with EQ001

- introduce clinical trial to determine whether high urinary levels of soluble CD6 and soluble ALCAM can be used as biomarker for sensitivity to treatment with EQ
- describe sample collection and treatment
- compare concentrations of soluble CD6 and soluble ALCAM between cohorts
- observe decreases in soluble CD6 and soluble ALCAM in subjects treated with EQ001
- support use of soluble CD6 and soluble ALCAM as biomarker for sensitivity to treatment with EQ001

### Treatment of Spontaneous SLE/Lupis Nephritis (LN) with CD6 Blockade

- introduce background and purpose of research
- describe MRL/MpJ-Faslpr/2J mouse strain as model of SLE and LN
- analyze renal CD6 and ALCAM expression in MRL/lpr mice
- confirm overexpression of CD6 and ALCAM in kidneys of MRL/lpr mice
- describe study design using MRL/lpr model
- treat mice with anti-CD6 antibody or isotype control
- monitor proteinuria, weights, and lymphadenopathy
- analyze terminal endpoints including urine albumin and creatinine levels
- analyze lymph node and spleen weights
- analyze renal-infiltrating immune cells
- show improved renal function and decreased mortality with anti-CD6 treatment
- show improved lymphadenopathy with anti-CD6 treatment
- show reduced kidney infiltrating immune cells with anti-CD6 treatment
- conclude that CD6 blockade decreases kidney damage and improves renal function and mortality

### Example 5

- introduce accelerated mouse model of nephrotoxic serum nephritis (NTN)
- describe NTN model characteristics
- outline experiment design
- describe treatment schedule
- introduce healthy control mice
- describe methods for inducing nephrotoxic serum nephritis
- outline treatment with anti-CD6 monoclonal antibody
- describe monitoring of kidney disease progression
- outline assessment of immune cell infiltration
- present results of CD6 blockade in NTN model
- show histological glomerular sections
- present glomerular and tubular scores
- show decreased proteinuria levels
- show improved albumin:creatinine ratios
- show improved BUN levels
- present RT-PCR results for renal cytokine levels
- show decreased immune cell accumulation
- show decreased inflammatory myeloid cells
- show decreased T cell populations
- introduce CD6-ALCAM pathway in NZB/W F1 and B6.Sle1yaa models of SLE
- describe serum ALCAM levels in NZB/W F1 and B6.Sle1yaa models
- present results of CD6 blockade in NZB/W F1 model

